menu search

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-house Cellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumab Cellectis stops enrollment and treatment of patients in the MELANI-01 clinical trial evaluating UCARTCS1 product candidate in r/r MM Encouraging preclinical data on TALEN®-edited MUC1 CAR T-cells presented […] The post Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 appe... Read More
Posted: May 4 2023, 20:30
Author Name: forextv
Views: 102518

Search within

Pages Search Results: